Duke Cancer researching immunotherapy, metastasis, and the immune microenvironment.
#FirstGen. USouthFlorida alumnus. Tufts residency survivor.
Patients don’t fail treatments, treatments fail patients.
Opinions=mine
In my 10+ years of going to #ASCO25 and this is the only one I have been impressed by. We get to make gift bags for kids at @luriecancer.bsky.social!!! Thats doing it right.
In my 10+ years of going to #ASCO25 and this is the only one I have been impressed by. We get to make gift bags for kids at @luriecancer.bsky.social!!! Thats doing it right.
2. Don’t fear the Ipi in Msi-h! Minimal toxicity increase but more CURES with Ipi combo over aPd1 monotherapy
3. Kras g12c is moving up and will likely achieve approvals in the near future
4. Stg 4 MSS CRC patients - sequence tumors at dx always!
2. Don’t fear the Ipi in Msi-h! Minimal toxicity increase but more CURES with Ipi combo over aPd1 monotherapy
3. Kras g12c is moving up and will likely achieve approvals in the near future
4. Stg 4 MSS CRC patients - sequence tumors at dx always!
Paraphrasing Dr. Ginhoux here, couldn’t agree more particularly in the era of single cell technologies.
Paraphrasing Dr. Ginhoux here, couldn’t agree more particularly in the era of single cell technologies.
Federally funding biomedical research makes American Dreams happen.
Federally funding biomedical research makes American Dreams happen.
pubmed.ncbi.nlm.nih.gov/37535729/
aacrjournals.org/cancerdiscov...
pubmed.ncbi.nlm.nih.gov/37535729/
aacrjournals.org/cancerdiscov...